Uppsala: Immunotherapy and Biomarkers Take Center Stage
In addition to immunotherapy, a meeting in Uppsala, Sweden, focused on recent progress in the development of novel disease biomarkers...
ALL NEWS
611 RESULTS
Sort By:
- Most Recent
- Most Commented
Subjective Memory Complaint—Not So Subjective Anymore?
People who complain of troubling memory lapses but show no impairment in standard memory tests may take some solace from a recent European study...
Seeking a Reliable Yardstick for ALS Trials
To determine if a medicine works, scientists need reliable patient data, but the right numbers are not always easy to come by...
Research Brief: APL1β28—Surrogate for CNS Aβ42 Production?
Calculating the risk of impending AD based on levels of CSF Aβ42 has been tricky because the peptide forms insoluble aggregates that muddle estimates of its production rate in the CNS...
Meet Progranulin, The Biomarker—A Simpler Story?
Scientists wrestling the complexities of α-synuclein fluid biochemistry might be forgiven for looking with some envy to a different protein of the neurodegenerative disease spectrum...
Still Early Days for α-synuclein Fluid Marker
Well over a decade of research into fluid biomarker candidates has reached a point where a so-called “pathological signature” of amyloid-β and tau proteins is beginning to emerge...
Ordnung, Please—Can Biomarkers Tame a Bewildering Overlap?
Tangible progress in dealing with spectrum diseases will remain limited until the field comes up with more and better biomarkers of their component proteins...
ADNI: Mission Creep From Alzheimer Disease to Healthy Senior?
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) was originally conceived as an exploratory project to identify the best measures for tracking disease progression...
ADNI: One-year Data Narrow Field of MRI, FDG-PET Approaches
Alzheimer imaging aficionados gathered for a peek at the latest data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)...
HAI Seattle: Biomarkers Closing in on AD Pathological Sequence?
The earliest pathological underpinnings of Alzheimer disease often precede symptoms by untold numbers of years, presenting researchers with a two-edged sword...
Risky Business—New Index Predicts Dementia in Older Adults
Unfortunately, there is no quick test for predicting Alzheimer disease (AD)—at least not yet...
News Brief: Scientists Net Prizes for Progress Toward ALS Biomarker
The nonprofit Prize4Life is awarding two scientific teams with $50,000 each at the American Academy of Neurology annual meeting in Seattle, Washington, this week...
Studies Reveal New Hope, Old Problems With AD Biomarkers
Brain imaging and cognitive tests may be the gold standards for tracking AD progression, but clinical trials using these procedures are expensive, risky, and time-consuming...
ADNI: GWA Nearly Complete, Biomarker Analysis Update
The Alzheimer’s Disease Neuroimaging Initiative announced this week that its genomewide analysis is 95 percent complete...
Keystone: Pulse-Chasing AD Biomarkers, Snaring γ-Secretase Targets
Two things you can find on any Alzheimerologist’s wish list are better drug targets and better diagnostics...
Current Filters
- Biomarkers x